Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials
Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials is drawing significant interest across the industry.
Jiangsu Hengrui Pharmaceuticals subsidiaries obtained the approval of China's drug administrator to start clinical trials for a novel combination therapy for non-small cell lung cancer, according...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Woman, 79, feels 50 years younger and it's all down to 3 things she did daily
- OpenAI expects $600 bn in compute spending through 2030 ahead of IPO
- Air India's aircraft fleet reliability has improved, says CEO Campbell Wilson
- Meet the world's smallest AI supercomputer - it packs 'doctorate-level intelligence', its makers say, and can fit into your pocket
Source: Original →